MedCity News Grifols reaches across the Atlantic and shells out $450M in a pair of M&A deals Grifols's acquisition of GigaGen comes as the startup's Covid-19 antibody drug is set to start Phase 1 testing. Barcelona-based Grifols says GigaGen’s technology could also help it expand to engineered antibody therapies. Shares0
Plasma is the lifeblood of Grifols, serving as the raw material for the biological medicines that generate most of the company’s revenue. But the Barcelona-based firm has eyed expansion beyond plasma-derived products and its acquisition of GigaGen offers the company the opportunity to add antibody drugs to its pipeline.